# Nightingale Health Shareholders Back Board, Authorize Buyback and Share Issue at 2026 AGM

> Nightingale Health's 2026 AGM approved no dividend, re-elected six directors and authorized buybacks of up to 1,952,643 A-series and 4,029,322 B-series shares.

- Published: 2026-11-05T15:42:54+00:00
- Section: Dividends & Buybacks
- Author: News Desk
- URL: https://newsforagent.com/news/2026-11-05/nightingale-health-agm-buyback-authorization
- Source: [TradingView](https://www.tradingview.com/news/modular_finance:c6d4d0cc2cb46:0-resolutions-of-the-annual-general-meeting-and-the-board-of-directors-organizational-meeting-of-nightingale-health-plc/)

## Key takeaways

- Nightingale Health's AGM resolved that no dividend be paid for the financial period 1 July 2025 to 30 June 2026, with the loss recorded in retained earnings.
- The board was authorized to repurchase up to 1,952,643 A-series and 4,029,322 B-series shares over 18 months.
- Leena Niemistö was elected chair of the six-member board at the organizational meeting held after the AGM.

[Nightingale Health](https://akta.pro/company-profiles/0002346/nightingale-health) Plc's annual general meeting on November 5, 2026 resolved that no dividend be distributed for the financial period 1 July 2025 to 30 June 2026 and that the period's loss be recorded in retained earnings, [TradingView](https://www.tradingview.com/news/modular_finance:c6d4d0cc2cb46:0-resolutions-of-the-annual-general-meeting-and-the-board-of-directors-organizational-meeting-of-nightingale-health-plc/) reported. The meeting also authorized the board to repurchase up to 1,952,643 A-series shares and 4,029,322 B-series shares.

## What Nightingale Health Shareholders Approved

The meeting was held as a fully virtual remote meeting under Chapter 5, Section 16, Subsection 3 of the Finnish Companies Act. Shareholders adopted the financial statements and consolidated financial statements for 1 July 2025 to 30 June 2026, granted discharge from liability to the board and CEO for that period, and approved the Remuneration Report in an advisory vote.

Six directors were re-elected: Antti Kangas, Olli Karhi, Ilkka Laurila, Leena Niemistö, Timo Soininen and Teemu Suna. The chair receives a monthly remuneration of EUR 4,000 and other members EUR 2,000. PricewaterhouseCoopers Oy was elected auditor, with Panu Vänskä as the auditor with principal responsibility.

The buyback authorization runs for 18 months and revokes the one granted at the November 6, 2025 annual general meeting. A separate authorization lets the board issue and convey up to 1,926,217 A-series shares and 4,064,778 B-series shares, plus convey up to 577,920 EMP-series shares held by the company, also valid 18 months. Both authorizations cover directed repurchases and issues, and the shares may be used for acquisitions, investments, financial structure or incentive schemes.

## Nightingale Health's Funding and Research Record

Nightingale Health is a Finnish public health technology company that measures 250 biomarkers from a single blood sample for multi-disease risk prediction, according to akta.pro [company records](https://akta.pro/company-data). The same records list total funding of $27.7 million at Series B, with the last round dated January 31, 2020, and a headcount range of 101-250.

## Deals Preceding the Annual Meeting

On October 28, 2026, Nightingale Health signed a USD 1 million proteomics agreement with LifeArc to analyze 10,000 UK Biobank samples using the NULISAseq Neuro 220 Panel, TradingView reported. On November 2, 2026, Alamar Biosciences and Nightingale Health launched the UK Biobank vanguard study to measure blood-based biomarkers for neurodegenerative diseases, TradingView reported. On November 5, 2026, the company received its first CLEP approvals for laboratory-developed tests from New York State, allowing its New York lab to offer them, TradingView reported.

## Nightingale Health's Next Date

The minutes of the annual general meeting will be available on the company's [website](https://www.nightingalehealth.com) on November 19, 2026 at the latest.

## Companies in this story

- [Nightingale Health company profile](https://akta.pro/company-profiles/0002346/nightingale-health) · website: https://www.nightingalehealth.com

---
News for Agent · https://newsforagent.com/llms.txt